Bayer’s Lynkuet, approved for treating moderate-to-severe vasomotor symptoms of menopause, targets two receptors key to ...

Tens of thousands of Kaiser Permanente workers in California and Hawaii have gone on strike, demanding safer staffing levels ...

CMS Administrator Dr. Mehmet Oz said that Medicaid’s rapid spending growth is unsustainable and criticized state financing ...

As always, this year's HLTH conference brought a slew of announcements — from product launches to funding rounds to new partnerships. This list features short summaries for seven of the conference’s ...

Bristol Myers Squibb is securing an opportunity to compete in the next generation of cell therapies through the $1.5 billion acquisition of Orbital Therapeutics, a startup with a lead program nearing ...

Marlow Hernandez, the founder and former CEO of Cano Health, was set to face a trial over allegations that he fraudulently enriched himself and his family while managing the senior-focused primary ...

With $50 billion set to flow to states over the next five years, CMS’ new Rural Health Transformation Program represents one of the largest federal investments in rural healthcare in decades. However, ...

Novo Nordisk is paying $240 million up front for global rights to zaltenibart, an Omeros drug that blocks the MASP-3 protein to treat diseases caused by excessive activity of the complement system.

Roughly 20 percent of the U.S. population resides in rural areas, and over 10 percent of the population lives in poverty. These individuals tend to feel the weight of provider shortages and high costs ...

Women’s health took the main stage at the HLTH Conference in Las Vegas on Monday. During a panel discussion, moderator Jodi Neuhauser, founder and CEO of 51&, detailed how the women’s healthcare ...

As healthcare providers, we often ask ourselves what success truly looks like for our patients. In a world where medicine grows more complex each day, the answer can feel uncertain. Yet when we pause ...